Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
Standard
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study). / Oluboka, Oloruntoba; Clerzius, Guerline; Janetzky, Wolfgang; Schöttle, Daniel; Therrien, François; Wiedemann, Klaus; Roy, Marc-André.
In: BMC PSYCHIATRY, Vol. 23, No. 1, 31.05.2023, p. 383.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
AU - Oluboka, Oloruntoba
AU - Clerzius, Guerline
AU - Janetzky, Wolfgang
AU - Schöttle, Daniel
AU - Therrien, François
AU - Wiedemann, Klaus
AU - Roy, Marc-André
N1 - © 2023. The Author(s).
PY - 2023/5/31
Y1 - 2023/5/31
N2 - BACKGROUND: Functional impairment affects many patients with schizophrenia. Treatment with the long-acting injectable antipsychotic aripiprazole once-monthly (AOM) may help improve functioning.OBJECTIVES: To explore changes in functioning in patients with schizophrenia who received AOM treatment in observational studies.METHODS: Here we report functional outcomes in the form of Global Assessment of Functioning (GAF) scores in a pooled analysis of data from two observational studies from Canada (NCT02131415) and Germany (vfa non-interventional studies registry 15960N). Data from 396 patients were analyzed.RESULTS: At baseline, the mean GAF score was 47.7 (SD 13.4). During 6 months of treatment with AOM, the mean GAF score increased to 59.4 (SD 15.8). Subgroups stratified by patient age (≤35 years/>35 years), sex, disease duration (≤5 years/>5 years) and disease severity at baseline had all significantly improved their GAF at month 6. 51.5% of the patients showed a GAF score increase of at least 10 points, which was regarded as clinically meaningful, and were considered responders.CONCLUSIONS: These data show that treatment with AOM may help improve patient functioning in a routine treatment setting.TRIAL REGISTRATION: NCT02131415 (May 6, 2014), vfa non-interventional studies registry 15960N.
AB - BACKGROUND: Functional impairment affects many patients with schizophrenia. Treatment with the long-acting injectable antipsychotic aripiprazole once-monthly (AOM) may help improve functioning.OBJECTIVES: To explore changes in functioning in patients with schizophrenia who received AOM treatment in observational studies.METHODS: Here we report functional outcomes in the form of Global Assessment of Functioning (GAF) scores in a pooled analysis of data from two observational studies from Canada (NCT02131415) and Germany (vfa non-interventional studies registry 15960N). Data from 396 patients were analyzed.RESULTS: At baseline, the mean GAF score was 47.7 (SD 13.4). During 6 months of treatment with AOM, the mean GAF score increased to 59.4 (SD 15.8). Subgroups stratified by patient age (≤35 years/>35 years), sex, disease duration (≤5 years/>5 years) and disease severity at baseline had all significantly improved their GAF at month 6. 51.5% of the patients showed a GAF score increase of at least 10 points, which was regarded as clinically meaningful, and were considered responders.CONCLUSIONS: These data show that treatment with AOM may help improve patient functioning in a routine treatment setting.TRIAL REGISTRATION: NCT02131415 (May 6, 2014), vfa non-interventional studies registry 15960N.
KW - Adult
KW - Humans
KW - Antipsychotic Agents/therapeutic use
KW - Aripiprazole/therapeutic use
KW - Canada
KW - Delayed-Action Preparations/therapeutic use
KW - Patient Acuity
KW - Schizophrenia/drug therapy
KW - Male
KW - Female
U2 - 10.1186/s12888-023-04893-8
DO - 10.1186/s12888-023-04893-8
M3 - SCORING: Journal article
C2 - 37259053
VL - 23
SP - 383
JO - BMC PSYCHIATRY
JF - BMC PSYCHIATRY
SN - 1471-244X
IS - 1
ER -
